Study S001442

Effect of GLP-1 on Insulin-dose, Risk of Hypoglycemia and Gastric Emptying Rate in Patients With Type 1 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT00993720
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2; PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 30
Start: 2009-10
Primary completion: 2010-10
Lead sponsor: Hvidovre University Hospital
Conditions: Diabetes Mellitus
Interventions: DRUG:Liraglutide; OTHER:continuous insulin therapy
Results posted: FALSE
Secondary identifiers: NIH:2009

Registered primary outcomes

insulin-dose [4 weeks]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0027162	Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function. Kielgast U, Diabetes care	2011	Randomized trial	PMID 21593296 DOI	cites ClinicalTrials.gov:NCT00993720; registry reference DERIVED:21593296
R0048071	Liraglutide Reduces Insulin Dose without Affecting Glycemic Control in T1DM Robert E. Buckley, MD Conference Express	2011	Randomized trial	DOI	cites ClinicalTrials.gov:NCT00993720